Effective and safe doses of opiate painkillers, like morphine, can be limited by respiratory depression. Schmid et al. (2017) now present a quantitative method to design ligands and correlate GPCR signaling bias to the dose separation between therapeutic and adverse effects in animals.
Overdose deaths from prescription opioids have quadrupled since the late 90's (National Academies of Sciences, Engineering, and Medicine, 2017) . Furthermore, those dependent on opioids, including chronic pain patients, are at higher risk for overdose due to slower development of tolerance to respiratory depression compared to analgesia (Boyer, 2012) . Therefore, it is important to increase the therapeutic window of opiates by creating drugs that maintain the ability to relieve pain at doses that do not impact respiration. Opiates target m-opioid receptors (MOR) in the brain stem and spinal cord to cause analgesia. Brain stem g-opioid activation also results in respiratory depression, which can lead to death. As a canonical Gi-coupled G-pro- effects (Manglik et al., 2016) . In this issue of Cell, Schmid et al. (2017) , through a series of rigorous and elegant pharmacology studies, demonstrate that the degree of bias toward G-protein versus arrestin pathways strongly correlates with the therapeutic window of the drug. This signature of activity provides the potential to separate the analgesic from the respiratory effects when designing more effective MOR ligands.
Neuropharmacology has been revolutionized recently by the discovery of biased ligands, providing a new avenue for developing more pathway selective, safer drugs, with a potential for increased patient compliance (Wacker et al., 2017) . Biased GPCR ligands preferentially engage through different signaling arms of a receptor's downstream messengers (Figure 1 ). Ligand bias can be quantified in rank order by calculating bias factor through the operational model (Kenakin et al., 2012 ). The operational model takes into account a consideration for a ligand's affinity and efficacy in comparison to a ''balanced'' ligand, which represents the full response at both G-protein and arrestin signaling. However, the chemical moieties that determine bias at most GPCRs, including MOR, remain unknown. Schmid et al. (2017) took on the heroic task to create a panel of MOR-selective compounds, ranging from higher G protein biases to complete arrestin bias, for quantitatively determining the chemical signatures that influence the existence and/or separation of signaling bias. Importantly, by using both in vitro and in vivo assays, these novel ligands were directly compared to widely used clinically relevant opiates (morphine, fentanyl, and sufenatnil).
Pioneering studies in arrestin knockout mice and recent studies on biased ligands have suggested that aversive side effects, including respiratory depression, may be due to arrestin bias (Manglik et al., 2016; Raehal et al., 2005) . However, whether the magnitude of G-protein bias improves therapeutic outcomes remained unknown. To address this gap, Schmid et al. (2017) examined the physiological effects of their novel MOR-selective toolbox in vivo. The team quantified the therapeutic window by comparing the median effective dose of each drug in a series of parallel analgesic and respiratory assays. The authors report a striking correlation between the degree of ligand bias and the therapeutic window of the drug. Although they used an empirical quantitative analysis method, the authors rightly stress that the absolute value of each calculation is not a static value but is instead determined by the context of the behavioral, physiological, or cellular assay employed. However, the authors do report here that the rank order of ligand bias is in fact preserved across multiple experimental assays.
This new research offers insight on the importance of evaluating the extent of a particular GPCR ligand's bias; a compound need not only be biased but could be calibrated for maximal bias to increase its therapeutic window in vivo. In addition, the authors introduce a ligand with the potential to study the functional effects of MOR arrestin signaling bias in brain and spinal cord circuits. This study also provides important insights into currently used analgesics: here, fentanyl is reported to be arrestin biased, which supports clinical evidence of a smaller therapeutic window (Schmid et al., 2017) . This research will inspire additional research on structure activity relationships to determine the conformation of the receptor that mediates G-protein or arrestin bias. Studies on the cellular signatures that these signaling pathways preferentially engage will be important as they facilitate a better understanding of how bias within specific neuronal populations is defined by cellular environment. Furthermore, studies determining the precise mechanisms by which arrestin signaling elicits respiratory depression, constipation, or as hypothesized, ''abuse liability'' remain important avenues to explore in the field. Chemical biology and pharmacology studies have revealed an incredible potential to harness bias for therapeutic benefit, yet our neurobiological understanding of these processes in brain and spinal circuits remains an exciting area of study. These new ligands and methods described by Schmid et al. (2017) will be crucial for assisting these efforts.
Figure 1. Effects of Biased Agonism on the Separation between Analgesia and Respiratory Depression
Compounds with arrestin bias (such as those with ethylendioxyl groups) have higher respiratory depression at lower doses through unknown signaling pathways, whereas G-protein-biased ligands (with halogen groups) exert analgesia with minimal respiratory depression through G i -coupled inhibition of voltage-gated calcium channels (Ca V 2) and activation of G-protein-coupled inwardly rectifying potassium channels (GIRK).
Considering the future extensions of this work, and the GPCR field at large, it will be interesting to continue characterizing the promising impact of bias factor on therapeutic window in additional pathways, GPCR systems, and neuronal contexts, as both bias factor and therapeutic index are contextdependent measures. In vitro, bias factor is dependent on the experimental assay; here, GTP hydrolysis was used to determine G-protein signaling. However, MOR signaling diverges downstream between ion channel modulation or kinase signaling pathways, including the Mitogen Activated Protein Kinases such as ERK and JNK pathways (Al-Hasani and Bruchas, 2011) . Analytically, bias factor calculation can also change based on the reference ligand chosen. If morphine were used as a reference ligand, some of these arrestin-biased ligands could possibly be re-classified as G protein biased relative to the weak arrestin recruitment induced by morphine. Finally, recent reports reveal that kinetics-or more practically, the time point of data collection in a given assay-is important in bias determination (Klein Herenbrink et al., 2016) . This consideration may have important effects on the interpretation of ligand bias on cellular function. Schmid et al. (2017) wisely account for temporal differences in behavior, yet future work may consider temporal differences in arrestin recruitment analysis, seeing as studies on opioid receptors have demonstrated that different ligands can recruit arrestin at different rates (Chang et al., 2015) . It will also be interesting to examine the therapeutic window for these drugs and the variety of other adverse effects such as reward, locomotion, constipation, and tolerance, all of which have been suggested to be sensitive to bias, acting via G-protein-and/or arrestin-dependent signaling arms (Manglik et al., 2016) . Finally, the species conservation of bias factors reported here will be an important and critical extension in the field at large, as many groups use mouse, rat, or other model systems. The authors here nicely addressed this issue, using both human and mouse receptors in vitro, and it will be important for the field to adopt similar rigor in comparing mouse and human bias factors.
In summary, Schmid et al. (2017) developed biased ligands and have empirically determined the physiological implications of their bias. In animal studies, the safety of biased opioid analgesics correlated with the GPCR signaling pathways that the compounds preferentially engage. This important avenue of research extends the current trend of rational ligand design by selecting bias that will increase therapeutic utility and drug safety.
